Clinical evaluation of traditional Chinese medicine on moderate active ulcerative colitis: a multi-center, randomized, double-blind, controlled trial

INTERVENTION: ?????????+???????(???)???:Qingchang Wenzhong Granules+Mesalazine Enteric‐coated Tablets(Salofalk)Simulator;Medical Group:Mesalazine Enteric‐coated Tablets(Salofalk)+Qingchang Wenzhong Granules Simulator;Combined Group:Qingchang Wenzhong Granules+Mesalazine Enteric‐coated Tablets(Salofalk); CONDITION: Ulcerative colitis PRIMARY OUTCOME: Clinical effective rate;Clinical remission rate; SECONDARY OUTCOME: Single symptom score;TCM syndrome score;Endoscopic response rate;Mucosal healing rate;Quality of life score; INCLUSION CRITERIA: 1. Diagnosis is in line with the active period of ulcerative colitis; 2. According to the improved Mayo score standard, the condition is moderate (score 6‐10 points); 3. Differentiation of TCM syndrome is heat‐dampness and stasis blocked accompanied with defeciency of spleen yang; 4. 18 to 65 years old; 5. Those who participate in this clinical study voluntarily, and have signed informed consent already.